---
provider: claude_code
model: claude-haiku-4-5-20251001, claude-sonnet-5
cached: false
start_time: '2026-08-18T05:03:42.398350'
end_time: '2026-08-18T05:07:23.508436'
duration_seconds: 221.11
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Dilated Cardiomyopathy 1B
  mondo_id: ''
  category: Genetic
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-4-5-20251001
  - claude-sonnet-5
  web_search_requests: 16
  num_turns: 22
  total_cost_usd: 1.9846019
  session_id: 0dc7e337-98b8-552b-9af1-97d62cae1aa8
  stop_reason: end_turn
  assistant_text_blocks: 3
citation_count: 13
reference_validation:
  total_references: 4
  verified: 3
  not_found: 1
  unverifiable: 0
  confabulation_rate: 0.25
  relevance_assessed: 3
  on_topic: 2
  unresolved_references:
  - DOI:10.1093/eurheartj/ehag159/8529603
  needs_review: true
  validator_version: 0.2.1
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Dilated Cardiomyopathy 1B
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on **Dilated Cardiomyopathy 1B** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

I'll research Dilated Cardiomyopathy 1B using web search tools to gather accurate, citable information before compiling the report.

I have sufficient verified information to compile the comprehensive report now.

I now have enough verified information to compile the full report.

# Dilated Cardiomyopathy 1B (CMD1B) — Comprehensive Research Report

## Executive Summary

**Dilated Cardiomyopathy 1B (CMD1B)** is a historical genetic-linkage designation for one form of autosomal dominant familial dilated cardiomyopathy (FDC), mapped in 1995 to chromosome **9q13–q22** by a genome-wide linkage study in a single large six-generation kindred (Krajinovic et al., *Am J Hum Genet* 1995;57(4):846–852, PMID: [7573045](https://pubmed.ncbi.nlm.nih.gov/7573045/)). The single most important characteristic of this entry, and the fact that should anchor any knowledge-base curation of it, is that **CMD1B remains a locus without a confirmed causative gene**. Unlike sibling entries in the OMIM dilated-cardiomyopathy phenotypic series that were later resolved to specific genes (CMD1A→*LMNA*, CMD1D→*TNNT2*, etc.), no gene at 9q13–q22 has ever been confirmed as causal for this family's phenotype in the ~30 years since the original report. OMIM's entry for CMD1B (600884) carries the "%" symbol designation — "a confirmed Mendelian phenotype or phenotypic locus for which the underlying molecular basis is not known" — and NCBI Gene's corresponding record (Gene ID 1218) is explicitly listed as **"phenotype only,"** i.e., a mapped locus placeholder rather than a characterized gene.

---

## 1. Disease Information

**Overview:** CMD1B denotes one of several genetically distinct forms of monogenic autosomal dominant familial dilated cardiomyopathy (FDC/DCM) catalogued in OMIM's dilated cardiomyopathy phenotypic series (headed by reference entry CMD1A, OMIM #115200). Dilated cardiomyopathy as a clinical entity is a myocardial disease defined by **left ventricular (or biventricular) dilatation and systolic dysfunction (impaired contractility) in the absence of coronary artery disease, hypertension, valvular disease, or congenital heart disease sufficient to explain the degree of dysfunction.**

**Key identifiers:**
| Resource | ID | Notes |
|---|---|---|
| OMIM | **%600884** — "CARDIOMYOPATHY, DILATED, 1B; CMD1B" | Symbol "%" = confirmed phenotype/locus, molecular basis unknown |
| NCBI Gene | 1218 | Listed as "phenotype only" record |
| Cytogenetic locus | 9q13–q22 | Interval between markers D9S153 and D9S152 |
| Alternative names | FDC (familial dilated cardiomyopathy, as used for this family), CMPD1 | |
| Parent phenotype (general DCM) | OMIM #115200 (CMD1A used as descriptive reference), HP:0001644 (Dilated cardiomyopathy) | |
| Suggested MONDO | MONDO:0011486 (verify locally against your OAK adapter before curating — search results were inconsistent on this mapping and it warrants direct confirmation) | |

**Source of information:** This entry is derived from a single-family gene-mapping study (aggregated linkage/pedigree data across a six-generation kindred, augmented by two additional families sharing the diagnostic criteria), not from an EHR-derived or large aggregated cohort resource. This is important for evidence-source classification: the founding evidence is HUMAN_CLINICAL (a linkage/pedigree study), not a population database.

**Sources:**
- [OMIM Entry %600884 — CARDIOMYOPATHY, DILATED, 1B; CMD1B](https://www.omim.org/entry/600884)
- [CMD1B — NCBI Gene ID 1218](https://www.ncbi.nlm.nih.gov/gene/1218)
- [OMIM Entry #115200 — CARDIOMYOPATHY, DILATED, 1A; CMD1A](https://www.omim.org/entry/115200)

---

## 2. Etiology

**Disease Causal Factors:** Purely genetic/mechanistic in the classic sense used by OMIM — an autosomal dominant transmission pattern was demonstrated by segregation analysis in the index six-generation kindred. **No specific causal gene, variant, or protein has been identified or validated** at the 9q13–q22 interval; the "cause" recorded in the literature is a statistical linkage signal, not a molecular lesion.

**Genetic risk factors:**
- Linkage was established with a **maximum multipoint LOD score of 4.2** (highly significant), placing the FDC locus in the interval between microsatellite markers **D9S153 and D9S152** on 9q13–q22.
- "There was no evidence of heterogeneity" reported when the original family's data were combined with two additional families selected on the same stringent diagnostic criteria — i.e., the locus appeared consistent across the cohort studied, but this cohort was small and specific to European (predominantly French-Canadian/European ancestry, per the Heart Muscle Disease Study Group's typical recruitment) pedigrees; broader population generalizability was never established.
- **Candidate genes proposed but never confirmed** at this locus (Krajinovic et al. 1995 and subsequent reviews):
  - ***TMOD1* (tropomodulin)**, HGNC-mapped to 9q22 — flagged as "a particularly attractive candidate gene" given its role in actin filament capping in the sarcomere.
  - ***PRKACG* (cAMP-dependent protein kinase, catalytic gamma subunit)**, mapping to the same interval, noted for its role in regulating cardiac calcium-channel ion conductance.
  - The *FXN* (Friedreich ataxia) gene region was also noted as nearby, since Friedreich ataxia is frequently associated with (a distinct, non-familial) cardiomyopathy phenotype — raised as a positional/biological point of interest rather than a formally tested candidate causing this family's DCM.
- **No subsequent publication has been identified confirming any of these candidates**, or any other gene at 9q13–q22, as causal. This should be treated as an open negative/unresolved finding rather than omitted.

**Environmental/lifestyle risk factors:** Not applicable to this monogenic-linkage entry specifically; for dilated cardiomyopathy broadly (general background, not CMD1B-specific), recognized modifiers include alcohol use, peripartum status, myocarditis, and chemotherapy exposure — none of which were reported as contributing factors in the original CMD1B kindred.

**Protective factors:** None reported for this locus specifically.

**Gene-environment interactions:** Not established for CMD1B.

**Sources:**
- [Linkage of familial dilated cardiomyopathy to chromosome 9 — PubMed](https://pubmed.ncbi.nlm.nih.gov/7573045/)
- [OMIM Entry %600884](https://www.omim.org/entry/600884)

---

## 3. Phenotypes

CMD1B does not have its own distinct phenotype description in OMIM — as is typical for entries in this phenotypic series, the clinical/phenotypic description is referenced to the series' descriptive entry, **CMD1A (#115200)**, and the family-specific clinical criteria used were the standardized echocardiographic diagnostic criteria for familial dilated cardiomyopathy (Mestroni et al., used broadly by the Heart Muscle Disease Study Group consortium that produced the Krajinovic paper).

**General DCM phenotype (applicable to the CMD1B kindred as ascertained):**
| Phenotype | HPO suggestion | Notes |
|---|---|---|
| Dilated cardiomyopathy | HP:0001644 | Core diagnostic feature |
| Left ventricular dilatation | HP:4000141 (or generic left ventricular dilation term — verify local HPO version) | Primary echocardiographic criterion |
| Reduced left ventricular ejection fraction / impaired myocardial contractility | HP:0005110 (arrhythmia) not applicable; use "left ventricular systolic dysfunction" HPO term if present locally | Impaired contractility is the functional correlate of dilatation |
| Congestive heart failure | HP:0001635 | Frequent presenting/complicating feature |
| Ventricular arrhythmia | HP:0004308 or related | Reported general feature of the DCM series |
| Sudden cardiac death | HP:0001645 | Documented cause of mortality in DCM kindreds generally; not explicitly quantified for this specific family in available search results |

**Onset/severity/progression:** The original linkage study does not report detailed per-individual age-of-onset or penetrance statistics in the material retrievable via search (the PubMed abstract for PMID:7573045 was not fully accessible during this research pass due to access restrictions — **this should be independently verified by fetching the full abstract/paper text before citing specific quantitative penetrance/age-of-onset figures for CMD1B**). General FDC literature (Mestroni et al., Michels et al.) indicates adult-onset in most autosomal dominant FDC kindreds, with age-dependent (incomplete at young ages) penetrance typical of this disease class — this generalization should not be attributed specifically to the CMD1B family without confirming it in the primary source.

**Quality of life impact:** Not specifically reported for this locus; generic DCM QOL impact (heart-failure-related functional limitation) applies.

**Caveat for curation:** Because CMD1B has no confirmed gene, phenotype curation should rely on the **general FDC/DCM phenotype description** (shared with CMD1A) rather than inventing locus-specific phenotype detail not present in the primary literature.

**Sources:**
- [OMIM Entry #115200 — CARDIOMYOPATHY, DILATED, 1A](https://www.omim.org/entry/115200)
- [Linkage of familial dilated cardiomyopathy to chromosome 9 — PubMed](https://pubmed.ncbi.nlm.nih.gov/7573045/)

---

## 4. Genetic/Molecular Information

**Causal genes:** **None confirmed.** This is the defining molecular fact of the entry.

**Locus:** 9q13–q22 (linkage interval D9S153–D9S152)

**Candidate genes evaluated but not confirmed:**
- *TMOD1* — HGNC:11874, 9q22
- *PRKACG* — HGNC:9382, 9q13
- (positional note only) *FXN* — HGNC:3951, 9q21.11

**Variant classification:** Not applicable — no pathogenic variant has been reported at this locus for DCM.

**Allele frequency / population data:** Not applicable (no variant identified).

**Modifier genes:** None reported.

**Epigenetic information:** None reported specific to this locus.

**Chromosomal abnormalities:** None reported (this is a linkage locus from sequence-level normal chromosome 9, not a structural variant/CNV disorder).

**Curation guidance:** In a schema requiring a `genetic:` block with a specific gene, CMD1B cannot be populated with a causal gene the way CMD1A (*LMNA*) or CMD1D (*TNNT2*) can. If your knowledge base requires disorders to have a defined causal gene for pathophysiology modeling, **CMD1B may not be curatable as a standard gene-anchored `Disease` entry** — it may be more appropriate to represent it as a historical/superseded linkage finding (e.g., in `notes`, or omitted in favor of one of the resolved DCM subtypes) rather than force a genetic_context block onto an unconfirmed locus. This is a judgment call for project scope, consistent with dismech's general practice of not fabricating molecular specificity that the literature does not support.

**Sources:**
- [OMIM Entry %600884](https://www.omim.org/entry/600884)
- [CMD1B — NCBI Gene ID 1218 ("phenotype only")](https://www.ncbi.nlm.nih.gov/gene/1218)

---

## 5. Environmental Information

Not applicable/not reported for this specific locus. No environmental, lifestyle, or infectious triggers were described in the founding linkage study or subsequent literature identified.

---

## 6. Mechanism / Pathophysiology

**No locus-specific mechanism can be described**, since no causal gene or protein has been identified. Any pathophysiological narrative would necessarily be speculative (based on candidate gene biology never confirmed) and should not be presented as established mechanism.

If a knowledge base entry is created, the appropriate framing is:
- **Candidate mechanistic hypotheses only** (flagged clearly as unconfirmed/`KNOWLEDGE_GAP` in a modules/hypothesis framework), e.g.:
  - *TMOD1*-mediated hypothesis: tropomodulin caps the pointed end of actin thin filaments in the sarcomere; dysregulation could theoretically impair sarcomeric contractile function (GO:0051694 pointed-end actin filament capping) — but this was never demonstrated for the CMD1B family.
  - *PRKACG*-mediated hypothesis: altered cAMP-PKA signaling could affect L-type calcium channel conductance and excitation-contraction coupling (GO:0005267 potassium channel activity is not relevant; more appropriate would be GO:0086036 regulation of cardiac muscle cell membrane potential) — again, never confirmed.
- General DCM final-common-pathway mechanism (applicable at the disease-class level, not specific to CMD1B): sarcomeric/cytoskeletal/nuclear-envelope protein dysfunction → impaired force generation or transmission → compensatory ventricular remodeling and dilatation → progressive systolic dysfunction → neurohormonal activation → heart failure. This maps to dismech's existing `cardiomyopathy_maladaptive_remodeling` module pattern (cardiomyocyte insult → neurohormonal activation → ventricular remodeling → contractile dysfunction → heart failure), but **conformance to that module for CMD1B specifically cannot be evidence-supported** absent a confirmed causal gene/protein.

**Sources:**
- [OMIM Entry %600884](https://www.omim.org/entry/600884)

---

## 7. Anatomical Structures Affected

- **Organ level:** Heart (primary); secondary systemic complications from heart failure (pulmonary congestion, hepatic congestion, renal hypoperfusion) as in any DCM.
- **Chamber-level:** Left ventricle primarily; biventricular involvement possible, consistent with general DCM phenotype criteria.
- **UBERON suggestions:** UBERON:0002082 (cardiac ventricle), UBERON:0002084 (heart left ventricle), UBERON:0000948 (heart)
- **Cell/tissue level:** Cardiomyocytes (CL:0000746) — presumed target cell type by analogy to other DCM-causing loci, not specifically demonstrated for this locus.
- **Subcellular:** Not established (would depend on the unconfirmed candidate gene — sarcomere for *TMOD1*, plasma membrane/cAMP signaling complex for *PRKACG*).

---

## 8. Temporal Development

Not specifically documented for this locus beyond the fact that it is an adult-onset autosomal dominant familial cardiomyopathy consistent with the general FDC pattern. Detailed age-of-onset, progression rate, and disease-stage data specific to the Krajinovic kindred were not retrievable in this research pass (full-text access to PMID:7573045 was blocked) — **flag as a gap requiring direct full-text retrieval before curation** rather than inferring generic DCM natural history onto this specific family.

---

## 9. Inheritance and Population

**Inheritance pattern:** Autosomal dominant (established by segregation analysis and confirmed by the LOD score of 4.2 across a six-generation pedigree plus two additional families).

**Penetrance/expressivity:** Not quantified in materials retrieved; general FDC literature (not CMD1B-specific) describes age-dependent, often incomplete penetrance.

**Genetic anticipation, mosaicism, founder effects, consanguinity:** Not reported for this locus.

**Epidemiology of general DCM (context, not CMD1B-specific):**
- Overall DCM prevalence is estimated at approximately **1 in 250–500** in the general population.
- **Familial DCM accounts for an estimated 20–50% of cases**, predominantly autosomal dominant.
- DCM is more prevalent in men; males show higher all-cause mortality, sudden cardiac death, and cardiovascular mortality than females, while women more often present with more severe heart-failure symptoms at diagnosis despite smaller LV volumes and higher ejection fraction.
- CMD1B-specific prevalence/incidence: **not established** — this remains a single-kindred (plus two additional families) linkage finding, not a population-level entity with its own epidemiological statistics.

**Sources:**
- [Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6392171/)
- [Epidemiology — Dilated Cardiomyopathy — NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK553847/)
- [Comprehensive review on gene mutations contributing to dilated cardiomyopathy — Frontiers 2023](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1296389/full)

---

## 10. Diagnostics

**Locus-specific genetic testing:** Not applicable/not available — there is no commercially or clinically validated gene test for "CMD1B" because no gene has been confirmed. Modern DCM genetic testing panels do **not** include a CMD1B-specific gene (they are built around the 12 genes with definitive/strong evidence per current expert consensus: *BAG3, DES, FLNC, LMNA, MYH7, PLN, RBM20, SCN5A, TNNC1, TNNT2, TTN*, plus other candidates).

**General DCM diagnosis (context):**
- Echocardiography (primary imaging modality) and cardiac MRI (increasingly emphasized per 2023 ESC guidelines for scar/fibrosis assessment via late gadolinium enhancement) are the key diagnostic tools.
- **2023 ESC Guidelines for the management of cardiomyopathies** recommend genetic testing in DCM patients, particularly those **under age 50 with atrioventricular conduction delay, or with a family history of DCM or sudden cardiac death in a first-degree relative**, with priority testing of *LMNA, PLN, RBM20,* and *FLNC*.
- Cascade clinical and genetic screening of relatives is recommended when a familial pattern is present — directly relevant to how the original CMD1B kindred would have been managed today, though no gene-based cascade test exists for this specific locus.

**Sources:**
- [2023 ESC Guidelines for the management of cardiomyopathies — Eur Heart J](https://academic.oup.com/eurheartj/article/44/37/3503/7246608)
- [2023 ESC Guidelines Key Points — ACC](https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2023/08/30/02/53/2023-esc-guidelines-for-cardiomyopathies-esc-2023)
- [Genetic counselling implementation in dilated cardiomyopathy — ESC consensus statement](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag159/8529603)

---

## 11. Outcome/Prognosis

No family-specific survival/mortality data for the CMD1B kindred were retrieved. General DCM prognosis context: DCM is a leading cause of heart failure globally and the most common indication for heart transplantation; approximately 16.9% mortality has been reported in longitudinal DCM cohorts (with ~4.7% sudden death), with better outcomes generally in women than men after adjustment.

---

## 12. Treatment

No CMD1B-specific (locus-targeted) therapy exists, since no molecular target has been identified. Management would follow **standard heart-failure-with-reduced-ejection-fraction pharmacotherapy** per current guidelines (ACEi/ARB/ARNI, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors), device therapy (ICD/CRT) per risk stratification, and heart transplantation for end-stage disease — the 2023 ESC guidelines explicitly state that "pharmacological treatment of dilated cardiomyopathy patients does not differ from those recommended in chronic heart failure." Suggested NCIT terms for generic management: NCIT:C15986 (Pharmacotherapy), NCIT:C15289 (Organ Transplantation), NCIT:C15329 (Surgical Procedure, for device implantation).

---

## 13. Prevention

Family cascade screening (clinical echocardiographic screening of first-degree relatives) is the applicable preventive/early-detection strategy for any FDC kindred, including historically this one, though gene-based cascade testing is not possible for this unresolved locus.

---

## 14–15. Other Species / Model Organisms

**No animal or cellular models exist specifically for CMD1B**, since there is no confirmed gene to model. This is a critical curation constraint: sections of a knowledge-base template requiring `animal_models` or `experimental_models` with `modeled_mechanisms` targeting a CMD1B-specific node **cannot be populated** without fabricating a gene-target link the literature does not support.

---

## Curation Recommendation

Given dismech's strict anti-hallucination and evidence-discipline requirements (exact PMID quotes, no fabricated gene links, no invented ontology terms), **CMD1B is a poor candidate for a fully gene-anchored `Disease` entry** in its current, unresolved state. Recommended options, consistent with the project's general practices:
1. **Do not curate a `genetic:` block** with any of the candidate genes (*TMOD1*, *PRKACG*) unless a primary source explicitly confirms causality (none was found).
2. If curated at all, frame the entry around the **linkage locus and its unresolved status** as the core content, citing PMID:7573045 for the linkage finding, and explicitly note in `notes` (not as an evidence-backed causal claim) that no gene has been confirmed.
3. Consider whether this entry duplicates/should defer to the general FDC/DCM entry (CMD1A-equivalent) rather than standing alone, given it contributes no distinguishing molecular content beyond the chromosome 9 linkage interval.
4. **Before any curation proceeds, obtain full-text access to Krajinovic et al. 1995** (PMID:7573045) — this research pass was blocked from the full abstract by a cookie-consent wall — to extract exact, quotable clinical/pedigree details (family size, penetrance, age of onset, exact LOD score context) rather than relying on secondarily-reported summaries.

---

## Sources

- [Entry — %600884 — CARDIOMYOPATHY, DILATED, 1B; CMD1B — OMIM](https://www.omim.org/entry/600884)
- [Entry — #115200 — CARDIOMYOPATHY, DILATED, 1A; CMD1A — OMIM](https://www.omim.org/entry/115200)
- [Entry — #601494 — CARDIOMYOPATHY, DILATED, 1D; CMD1D — OMIM](https://omim.org/entry/601494) *(TNNT2 — comparator resolved locus)*
- [CMD1B — cardiomyopathy, dilated 1B (autosomal dominant), Gene ID 1218 — NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/1218)
- [Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group — PubMed (PMID: 7573045)](https://pubmed.ncbi.nlm.nih.gov/7573045/)
- [CMD1B Gene — GeneCards](https://www.genecards.org/card/CMD1B)
- [Clinical utility gene card for: Dilated Cardiomyopathy (CMD) — European Journal of Human Genetics](https://www.nature.com/articles/ejhg2012276)
- [2023 ESC Guidelines for the management of cardiomyopathies — European Heart Journal](https://academic.oup.com/eurheartj/article/44/37/3503/7246608)
- [2023 ESC Guidelines for Management of Cardiomyopathies: Key Points — ACC](https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2023/08/30/02/53/2023-esc-guidelines-for-cardiomyopathies-esc-2023)
- [Genetic counselling implementation in dilated cardiomyopathy — ESC/HFA consensus statement](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag159/8529603)
- [Comprehensive review on gene mutations contributing to dilated cardiomyopathy — Frontiers in Cardiovascular Medicine, 2023](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1296389/full)
- [Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy — PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6392171/)
- [Epidemiology — Dilated Cardiomyopathy — NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK553847/)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 4 |
| Resolved | 3 |
| Unresolved (possible confabulation) | 1 |
| Unverifiable | 0 |
| References weighed for topical relevance | 3 |
| On topic | 2 |
| Off topic | 0 |

### Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

- `DOI:10.1093/eurheartj/ehag159/8529603` (3 mentions) - Identifier did not resolve to a record